

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(**深圳市海普瑞藥業集團股份有限公司**)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(**Stock code: 9989**)

**CHANGE OF JOINT COMPANY SECRETARY AND
AUTHORIZED REPRESENTATIVE
AND
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28
AND 8.17 OF THE LISTING RULES**

The Board announces that (i) Ms. Tan has resigned from her positions as a Joint Company Secretary and an Authorized Representative, with effect from October 27, 2021; (ii) Mr. Qian has been appointed as a Joint Company Secretary and an Authorized Representative, with effect from October 27, 2021; and (iii) the Company has applied to the Stock Exchange and has been granted a waiver by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules.

The board (the “**Board**”) of directors of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) announces that Ms. Tan Xuan (“**Ms. Tan**”) resigned as (i) a joint company secretary of the Company (the “**Joint Company Secretary**”); and (ii) an authorized representative (the “**Authorized Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) with effect from October 27, 2021, in order to pursue other business and work commitments, which makes her no longer possible to spend sufficient time on the business of the Company.

Ms. Tan has confirmed that she has no disagreement with the Board and that there are no other matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board further announces that Mr. Qian Fengqi (“**Mr. Qian**”) has been appointed as a Joint Company Secretary and an Authorized Representative, with effect from October 27, 2021.

The biographical details of Mr. Qian are set out as follows:

Mr. Qian Fengqi (錢風奇), aged 36, is experienced in capital market research and investment matters, in particular in the healthcare industry in the People’s Republic of China (the “**PRC**”). Mr. Qian joined the Company as the president of investment center (投資中心總監) in August 2021, primarily responsible for overseeing the investment activities of the Company in the healthcare field. Mr. Qian served as a research analyst at Boser Fund Management from July 2008 to March 2010, a senior research analyst at Goldman Sachs Group (China) from August 2010 to August 2013, and a fund manager of Norges Bank, which manages the assets of the sovereign wealth fund of Norway, from September 2013 to April 2016, each with a focus on investments in listed securities of PRC-based healthcare companies. Mr. Qian also served as a managing director of Lingfeng Capital Management Co., Ltd. (領風資本管理有限公司), a private equity fund with a focus on the fintech sector in the PRC, from January 2017 to August 2019 and from November 2020 to August 2021, and the head of Strategic Investment Department of We Doctor Group (Zhejiang) Co., Ltd. (微醫集團(浙江)有限公司), a digital medical service provider in the PRC, from August 2019 to November 2020. Mr. Qian graduated from Fudan University with a bachelor of economics (specialising in finance) degree in July 2008.

Mr. Qian obtained the board secretary certificate granted by the Shenzhen Stock Exchange in September 2021. Currently, he does not hold any shares of the Company, has no relationship with shareholders holding more than 5% of the shares of the Company, directors, supervisors, or senior management personnel of the Company, and has not been subject to any disciplinary action by the China Securities Regulatory Commission and other relevant departments and the punishment of exchanges.

Having considered Mr. Qian’s background and experience, the Board is of the view that, although Mr. Qian is yet to possess the qualifications of a company secretary as required under Rule 3.28 of the Listing Rules, he is capable of discharging his functions as a Joint Company Secretary. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules with respect to the eligibility of Mr. Qian to act as a Joint Company Secretary (the “**Waiver**”) for a period of three years from the date of such appointment, being October 27, 2021 (the “**Waiver Period**”).

The granting of the Waiver is conditional upon that (i) Mr. Qian will be assisted by Ms. Chan Sze Ting (“**Ms. Chan**”), the other Joint Company Secretary, to acquire the relevant experience and discharge his functions as a Joint Company Secretary during the Waiver Period; (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company; and (iii) the Company will announce the reasons, details and conditions of the Waiver, and the qualification and experience of both Mr. Qian and Ms. Chan. The Waiver will be revoked immediately if and when Ms. Chan ceases to be a Joint Company Secretary. The Stock Exchange may withdraw or change the Waiver if the situation of the Company changes. Before the end of the Waiver Period, the Company shall notify the Stock Exchange to re-visit the situation. The Company expects to demonstrate that Mr. Qian can satisfy Rules 3.28 and 8.17 of the Listing Rules at the end of the Waiver Period, having had the benefit of Ms. Chan’s assistance during the Waiver Period, such that a further waiver would not be necessary.

The biographical details of Ms. Chan are set out as follows:

Ms. Chan Sze Ting (陳詩婷) is a Joint Company Secretary. Ms. Chan currently serves as an associate director of corporate services of Tricor Services Limited, a global professional services provider specializing in integrated business, corporate and investor services. Ms. Chan has over 15 years of experience in the corporate secretarial field. She has been providing professional corporate services to multiple Hong Kong listed companies. Ms. Chan is currently a joint company secretary of Sinopec Shanghai Petrochemical Company Limited (a company listed on the Main Board of the Stock Exchange, stock code: 338 and listed on the Shanghai Stock Exchange, stock code: 600688), the company secretary of Sunfonda Group Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 1771), Modern Media Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 72), Century Sage Scientific Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 1450) and Vico International Holdings Limited (a company listed on the Main Board of the Stock Exchange, stock code: 1621). Ms. Chan is a Chartered Secretary, a Chartered Governance Professional and an Associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Ms. Chan holds a bachelor of laws degree from the University of London.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Tan for her valuable contributions to the Company during her tenure of service and extend its warm welcome to Mr. Qian on his new appointment.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
October 27, 2021

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.